Eurachem published one guide on measurement uncertainty. ECA reported the update on May 21, 2026. The first edition was released in March 2026. It uses precision and recovery data from in-house validation. Poor uncertainty estimates can distort pharmaceutical compliance decisions.
Why Does Eurachem Link Uncertainty With Validation?
Eurachem’s 2026 guide explains how laboratories can estimate measurement uncertainty from intermediate precision and recovery studies. It links in-house validation, HPLC performance, and ISO/IEC 17025 decision requirements. The problem is that laboratories may report precise-looking results without quantifying uncertainty across concentrations. That gap can weaken specification comparisons, conformity assessments, and confidence in whether analytical results remain fit for purpose consistently.
Uncertainty Gaps Threaten Laboratory Decisions
Poor measurement uncertainty models can misclassify passing or failing results, trigger incorrect OOS investigations, delay batch release, and weaken regulatory confidence. HPLC data, reference materials, and analytical method validation must support the same decision. However, Eurachem’s approach creates a positive opportunity. Laboratories can reuse precision and recovery evidence, model uncertainty across concentration ranges, and set decision rules. Stronger estimates may reduce false conclusions while improving traceability, compliance, and patient protection.
Why Eurachem, HPLC, and ISO 17025 Matter to Pharma Professionals
Measurement uncertainty affects quality control analysts, method-validation scientists, and quality assurance professionals. Each group must connect Eurachem guidance, HPLC performance, and ISO/IEC 17025 expectations with specification decisions. Their combined work determines whether laboratory conclusions remain accurate, traceable, and defensible consistently.
Quality Control and Laboratory Teams
Quality control analysts must understand how uncertainty affects specification comparisons and OOS decisions. Incomplete estimates can make borderline HPLC results appear conclusive, creating unsupported batch-release or rejection decisions during testing.
- Review uncertainty before reporting borderline results.
- Escalate inconclusive data before batch disposition.
Analytical Method Validation Scientists
Method-validation scientists must use precision, recovery, concentration range, and reference-material evidence correctly. Weak models can underestimate uncertainty, obscure systematic effects, and produce methods unsuited for intended pharmaceutical decisions in practice.
- Model uncertainty across validated concentration ranges.
- Investigate divergent recovery values scientifically.
Quality Assurance Professionals
Quality assurance professionals must verify that uncertainty procedures, calculations, and decision rules are approved and followed. Missing governance can weaken data integrity, inspection readiness, and confidence in final compliance conclusions.
- Approve uncertainty procedures and decision rules.
- Audit calculations against source validation data.
What Could Stronger Uncertainty Estimates Achieve?
Eurachem’s first 2026 guide gives laboratories a structured method for using precision and recovery data. Better uncertainty estimates may improve conformity assessments, reduce false OOS conclusions, and support reliable batch decisions. Companies should now review validation datasets, concentration models, decision rules, and SOPs before applying results to product specifications routinely.
Want to strengthen analytical decision-making? Read Pharmuni’s The Hidden Risks in Analytical Method Validation to understand accuracy, precision, robustness, documentation, and compliance risks. Apply these lessons to HPLC validation, measurement uncertainty, OOS investigations, and more defensible pharmaceutical quality decisions.